Also known as Zytiga.
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
CHMP backs AKEEGA® for mHSPC with BRCA1/2 mutations, showing improved progression-free survival and manageable safety profile in Phase 3 AMPLITUDE study.
FDA approves AKEEGA for BRCA2-mutated prostate cancer, reducing disease progression by 54% and delaying symptoms by 59% in clinical trials.
FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.
